Author(s): Ľudovít GAŠPAR – Iveta GAŠPAROVÁ

Title: VYSOKONÁKLADOVÁ ONKOLOGICKÁ LIEČBA A MEDICÍNSKA ETIKA

Source: E. Korcsmáros (ed.): 12th International Conference of J. Selye University. Economics Section. Conference Proceedings

ISBN: 978-80-8122-375-4

DOI: https://doi.org/10.36007/3754.2020.167

Publisher: J. Selye University, Komárno, Slovakia

PY, pages: 2020, 167-172

Published on-line: 2020

Language: sk

Abstract: Cardiovascular and oncological diseases, with their incidence, prevalence and serious impact on the health status of the population, are of societal importance also in terms of the financial demands of their diagnostics and especially treatment. Therefore, it is important to reduce the incidence and mortality of these diseases and to improve the patients quality of life through a systematic implementation of evidence-based strategies. Despite the fact that survival in selected oncological diseases is rising, the epidemiological parameters in Slovakia are still worse than the average of European Union countries. Given the limited financial resources in the health system and the high prevalence of these diseases, a fair and transparent process of financing this sector is necessary. Health Technology Assessment or HTA is currently the major challenge in appraisal of medical innovations and healthcare systems. The accord of the economic sustainability of the health care financing system with the professional competence and moral integrity of health care workers is important, together with the social availability of adequate treatment for every citizen of the Slovak Republic. The aim of our work is to point out the need to apply the HTA methodology to clinical practice in terms of the concept of value for money.

Keywords: Oncological diseases - Health technology assessment - Drug policy - Costs effectivness - Medical ethics

Fulltext (PDF)